The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry*-Reference-Cited by-同舟云学术

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry*

Published:1996-11 Issue:5 Volume:60 Page:522-534
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Chen Shuqing,Chou Wen-Hwei,Blouin Robert A.,Mao Zhongping,Humphries Laurie L.,Meek Q. Craig,Neill John R.,Martin Walter L.,Hays Lon R.,Wedlund Peter J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference42 articles.

1. Clinical significance of the sparteine/debrisoquine oxidation polymorphism

2. Pharmacogenetic Phenotyping and Genotyping

3. “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism

4. [15] Isolation of genomic DNA

5. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?;Frontiers in Genetics;2020-12-08

2. Pharmacogenomics and Psychopharmacology;Seminars in Clinical Psychopharmacology;2020-06-18

3. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline;Expert Opinion on Drug Metabolism & Toxicology;2019-09-02

4. Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP;The Pharmacogenomics Journal;2019-01-31

5. Pharmacogenomics in Psychiatric Disorders;Pharmacogenomics;2019